Fredrik Alpsten

Styrelseordförande | Verkställande direktör (VD)

Profile key: se|fredrik alpsten

Purchase history

Companies traded: 5
Purchases · 12M: 7
Purchases · 24M: 10
Average purchase: SEK 569,338
Gross purchase value: SEK 5,693,377
Last purchase: 2026-09-10
Completed 20D events: 10.0
Outcome status: PASS

Latest company: Biovica International AB

Companies: Biovica International AB | Devyser Diagnostics AB | Prolight Diagnostics | Prolight Diagnostics AB | Prolight Diagnostics AB (publ)

Post-purchase outcomes

Benchmark-relative outcomes are available against OMX Stockholm 30.

Excess return = stock return − OMX Stockholm 30 return over the same period.
Hit rate = positive excess-return events ÷ completed events.
Price coverage = valid point-in-time prices ÷ events mature enough for that period.
Returns start on the first shared trading session on or after publication.

Period	Completed events	Price coverage	Hit rate	Median excess return	Average excess return	Worst excess return
5D	10Developing	100.0% (10/10)	70.0% (7/10)	+1.1%	+990.5%	-7.2%
20D	10Developing	100.0% (10/10)	60.0% (6/10)	+6.2%	+996.0%	-7.5%
60D	9Developing	100.0% (9/9)	11.1% (1/9)	-7.0%	+1087.1%	-42.0%
120D	6Developing	100.0% (6/6)	83.3% (5/6)	+4946.9%	+4942.3%	-21.0%

Research patterns

First purchase in 12M: 3/7
Large purchase ≥ €100k: 1/10
Cluster buying · 15D: 3/10
Buying the dip · ≥20% below prior 52W high: 8/10
Routine / opportunistic: Not classifiable

Counts are profile-wide, point-in-time research labels. They never affect the insider score or ranking.

Every completed outcome is shown; n<5 is descriptive small-sample evidence and is not scored. Disclosure-level observations published on the same date may share a return path and may not be statistically independent. These results never affect the insider score or ranking.